A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma

Journal of Hematology and Oncology

Volumn 7, Issue 1, 2014, Pages

  Yuan, Jianping ^a   Kashiwagi, Satoshi ^a   Reeves, Patrick ^a   Nezivar, Jean ^a   Yang, Yuan ^a   Arrifin, Nadiah Hashim ^a   Nguyen, Mai ^a   Jean Mary, Gilberte ^a   Tong, Xiaoyun ^a   Uppal, Paramjit ^a   Korochkina, Svetlana ^a   Forbes, Ben ^a   Chen, Tao ^a   Righi, Elda ^a   Bronson, Roderick ^b   Chen, Huabiao ^c   Orsulic, Sandra ^d   Brauns, Timothy ^a   Leblanc, Pierre ^a   Scholler, Nathalie ^e   Dranoff, Glenn ^f,g   Gelfand, Jeffrey ^a   Poznansky, Mark C ^a   more..

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD UNIVERSITY   (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f DANA FARBER CANCER INSTITUTE   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cancer immunotherapy; Mesothelin; Murine tumor model; Mycobacterial Hsp70; Single chain variable fragment

Indexed keywords

ANTINEOPLASTIC AGENT; BACTERIAL PROTEIN; GAMMA INTERFERON; GRANZYME B; HEAT SHOCK PROTEIN 70; HYBRID PROTEIN; MESOTHELIN; MYCOBACTERIUM TUBERCULOSIS HEAT SHOCK PROTEIN 70; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; CANCER VACCINE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES; BONE MARROW CELL; CANCER CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CELL AGGREGATION; CELL MATURATION; CELL MIGRATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; LYMPHOCYTE DEPLETION; MALE; MALIGNANT MESOTHELIOMA; MESOTHELIOMA; MESOTHELIUM CELL; MONOCYTE; MOUSE; MULTIPLE CYCLE TREATMENT; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SPLEEN CELL; T CELL DEPLETION; TUMOR IMMUNITY; ANIMAL; C57BL MOUSE; DISEASE FREE SURVIVAL; DISEASE MODEL; GENETICS; HUMAN; IMMUNOLOGY; LUNG NEOPLASMS; OVARIAN NEOPLASMS; SURVIVAL;

ANIMALS; CANCER VACCINES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; DISEASE-FREE SURVIVAL; FEMALE; GPI-LINKED PROTEINS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; MICE; MICE, INBRED C57BL; OVARIAN NEOPLASMS; RECOMBINANT PROTEINS; SURVIVAL ANALYSIS;

EID: 84895924146     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-7-15     Document Type: Article

References (48)

1. Dendritic cells as therapeutic vaccines against cancer. Banchereau J, Palucka AK, Nature reviews Immunology 2005 5 296 306 10.1038/nri1592 15803149
2. Cancer immunotherapy comes of age. Mellman I, Coukos G, Dranoff G, Nature 2011 480 480 489 10.1038/nature10673 22193102
3. Cancer immunotherapy comes of age. Topalian SL, Weiner GJ, Pardoll DM, J Clin Oncol 2011 29 4828 4836 10.1200/JCO.2011.38.0899 22042955
4. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, IMPACT Study Investigators, The New England journal of medicine 2010 363 411 422 10.1056/NEJMoa1001294 20818862
5. Listening to provenge-what a costly cancer treatment says about future medicare policy. Chambers JD, Neumann PJ, The New England journal of medicine 2011 364 1687 1689 10.1056/NEJMp1103057 21470004
6. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Chang K, Pastan I, Proc Natl Acad Sci USA 1996 93 136 140 10.1073/pnas.93.1.136 8552591
7. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Argani P, Iacobuzio-Donahue C, Ryu B, Rosty C, Goggins M, Wilentz RE, Murugesan SR, Leach SD, Jaffee E, Yeo CJ, Cameron JL, Kern SE, Hruban RH, Clinical cancer research: an official journal of the American Association for Cancer Research 2001 7 3862 3868 11751476
8. Mesothelin expression in human lung cancer. Ho M, Bera TK, Willingham MC, Onda M, Hassan R, FitzGerald D, Pastan I, Clinical cancer research: an official journal of the American Association for Cancer Research 2007 13 1571 1575 10.1158/1078-0432.CCR-06-2161 17332303
9. The role of mesothelin in tumor progression and targeted therapy. Tang Z, Qian M, Ho M, Anti-cancer agents in medicinal chemistry 2013 13 276 280 10.2174/1871520611313020014
10. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, Willingham MC, Pastan I, Clinical cancer research: an official journal of the American Association for Cancer Research 2007 13 5144 5149 10.1158/1078-0432.CCR-07-0869 17785569
11. Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I, Clinical cancer research: an official journal of the American Association for Cancer Research 2009 15 5274 5279 10.1158/1078-0432.CCR-09-0062 19671873
12. Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library. Feldhaus MJ, Siegel RW, Opresko LK, Coleman JR, Feldhaus JM, Yeung YA, Cochran JR, Heinzelman P, Colby D, Swers J, Graff C, Wiley HS, Wittrup KD, Nature biotechnology 2003 21 163 170 10.1038/nbt785 12536217
13. Development and in vitro validation of anti-mesothelin biobodies that prevent CA125/Mesothelin-dependent cell attachment. Bergan L, Gross JA, Nevin B, Urban N, Scholler N, Cancer Lett 2007 255 263 274 10.1016/j.canlet.2007.04.012 17560019
14. Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA. Scholler N, Lowe KA, Bergan LA, Kampani AV, Ng V, Forrest RM, Thorpe JD, Gross JA, Garvik BM, Drapkin R, Anderson GL, Urban N, Clinical cancer research: an official journal of the American Association for Cancer Research 2008 14 2647 2655 10.1158/1078-0432.CCR-07-1442 18451228
15. Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor. Lanitis E, Poussin M, Hagemann IS, Coukos G, Sandaltzopoulos R, Scholler N, Powell DJ Jr, Molecular therapy: the journal of the American Society of Gene Therapy 2012 20 633 643 10.1038/mt.2011.256 22127019
16. CD40 is a cellular receptor mediating mycobacterial heat shock protein 70 stimulation of CC-chemokines. Wang Y, Kelly CG, Karttunen JT, Whittall T, Lehner PJ, Duncan L, MacAry P, Younson JS, Singh M, Oehlmann W, Cheng G, Bergmeier L, Lehner T, Immunity 2001 15 971 983 10.1016/S1074-7613(01)00242-4 11754818
17. Dendritic cell stimulation by mycobacterial Hsp70 is mediated through CCR5. Floto RA, MacAry PA, Boname JM, Mien TS, Kampmann B, Hair JR, Huey OS, Houben EN, Pieters J, Day C, Oehlmann W, Singh M, Smith KG, Lehner PJ, Science 2006 314 454 458 10.1126/science.1133515 17053144
18. Effect of recombinant heat shock protein 70 of mycobacterial origin on cytotoxic activity and immunophenotype of human peripheral blood mononuclear leukocytes. Vorobiev DS, Kiselevskii MV, Chikileva IO, Semenova IB, Bulletin of experimental biology and medicine 2009 148 64 67 10.1007/s10517-009-0622-z 19902099
19. Differential MyD88/IRAK4 requirements for cross-priming and tumor rejection induced by heat shock protein 70-model antigen fusion protein. Mizukami S, Kajiwara C, Tanaka M, Kaisho T, Udono H, Cancer science 2012 103 851 859 10.1111/j.1349-7006.2012.02233.x 22320267
20. Vaccination with B16 tumor cell lysate plus recombinant Mycobacterium tuberculosis Hsp70 induces antimelanoma effect in mice. Li H, Yu Y, Sun L, Wang H, Zhang P, Wei H, Wang L, Wan M, Cao Z, Wang Y, Chen Y, Dong B, Wang L, Cancer biotherapy & radiopharmaceuticals 2010 25 185 191 10.1089/cbr.2009.0716 20423232
21. Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene. Cheng WF, Hung CF, Chai CY, Hsu KF, He L, Rice CM, Ling M, Wu TC, J Immunol 2001 166 6218 6226 11342644
22. A novel vaccine strategy to induce mycobacterial antigen-specific Th1 responses by utilizing the C-terminal domain of heat shock protein 70. Uto T, Tsujimura K, Uchijima M, Seto S, Nagata T, Suda T, Chida K, Nakamura H, Koide Y, FEMS immunology and medical microbiology 2011 61 189 196 10.1111/j.1574-695X. 2010.00762.x 21204994
23. Fusion of HSP70 gene of Mycobacterium tuberculosis to hemagglutinin (H5) gene of avian influenza virus in DNA vaccine enhances its potency. Rasoli M, Omar AR, Aini I, Jalilian B, Syed Hassan SH, Mohamed M, Acta virologica 2010 54 33 39 10.4149/av-2010-01-33 20201612
24. Mycobacterial HSP70 as an adjuvant in the design of an idiotype vaccine against a murine lymphoma. Karyampudi L, Ghosh SK, Cell Immunol 2008 254 74 80 10.1016/j.cellimm.2008.07.003 18715553
25. CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Righi E, Kashiwagi S, Yuan J, Santosuosso M, Leblanc P, Ingraham R, Forbes B, Edelblute B, Collette B, Xing D, Kowalski M, Mingari MC, Vianello F, Birrer M, Orsulic S, Dranoff G, Poznansky MC, Cancer research 2011 71 5522 5534 10.1158/0008-5472. CAN-10-3143 21742774
26. Intradermal injection, as opposed to subcutaneous injection, enhances immunogenicity and suppresses tumorigenicity of tumor cells. Bonnotte B, Gough M, Phan V, Ahmed A, Chong H, Martin F, Vile RG, Cancer research 2003 63 2145 2149 12727832
27. Mycobacterium tuberculosis heat-shock protein 70 impairs maturation of dendritic cells from bone marrow precursors, induces interleukin-10 production and inhibits T-cell proliferation in vitro. Motta A, Schmitz C, Rodrigues L, Ribeiro F, Teixeira C, Detanico T, Bonan C, Zwickey H, Bonorino C, Immunology 2007 121 462 472 10.1111/j.1365-2567.2007.02564.x 17346283
28. Calcium signaling in dendritic cells by human or mycobacterial Hsp70 is caused by contamination and is not required for Hsp70-mediated enhancement of cross-presentation. Bendz H, Marincek BC, Momburg F, Ellwart JW, Issels RD, Nelson PJ, Noessner E, The Journal of biological chemistry 2008 283 26477 26483 10.1074/jbc.M803310200 18658155
29. Identification of stimulating and inhibitory epitopes within the heat shock protein 70 molecule that modulate cytokine production and maturation of dendritic cells. Wang Y, Whittall T, McGowan E, Younson J, Kelly C, Bergmeier LA, Singh M, Lehner T, J Immunol 2005 174 3306 3316 15749862
30. The role of heat shock proteins in antigen cross presentation. Murshid A, Gong J, Calderwood SK, Frontiers in immunology 2012 3 63 22566944
31. In vivo cytotoxic T lymphocyte elicitation by mycobacterial heat shock protein 70 fusion proteins maps to a discrete domain and is CD4(+) T cell independent. Huang Q, Richmond JF, Suzue K, Eisen HN, Young RA, The Journal of experimental medicine 2000 191 403 408 10.1084/jem.191.2.403 10637285
32. The adjuvant effects of Mycobacterium tuberculosis heat shock protein 70 result from the rapid and prolonged activation of antigen-specific CD8+ T cells in vivo. Harmala LA, Ingulli EG, Curtsinger JM, Lucido MM, Schmidt CS, Weigel BJ, Blazar BR, Mescher MF, Pennell CA, J Immunol 2002 169 5622 5629 12421941
33. Cancer immunotherapy by dendritic cells. Melief CJ, Immunity 2008 29 372 383 10.1016/j.immuni.2008.08.004 18799145
34. CD8+ T cell priming by dendritic cell vaccines requires antigen transfer to endogenous antigen presenting cells. Yewdall AW, Drutman SB, Jinwala F, Bahjat KS, Bhardwaj N, PloS one 2010 5 11144 10.1371/journal.pone.0011144 20585396
35. Building on dendritic cell subsets to improve cancer vaccines. Palucka K, Ueno H, Zurawski G, Fay J, Banchereau J, Current opinion in immunology 2010 22 258 263 10.1016/j.coi.2010.02.010 20226644
36. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. Bonifaz L, Bonnyay D, Charalambous A, Darguste D, Fujii S, Soares H, Brimnes M, Moltedo B, Moran T, Steinman R, The Journal of experimental medicine 2004 199 815 824 10.1084/jem.20032220 15024047
37. Targeting of the non-mutated tumor antigen HER2/neu to mature dendritic cells induces an integrated immune response that protects against breast cancer in mice. Wang B, Zaidi N, He LZ, Zhang L, Kuroiwa JM, Keler T, Steinman RM, Breast cancer research: BCR 2012 14 39 10.1186/bcr3135 22397502
38. The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells. Wang B, Kuroiwa JM, He LZ, Charalambous A, Keler T, Steinman RM, Ann N Y Acad Sci 2009 1174 6 17 10.1111/j.1749-6632.2009.04933.x 19769731
39. Enhanced T-Cell responses to glioma cells coated with the anti-EGF receptor antibody and targeted to activating Fc[gamma]Rs on human dendritic cells. Banerjee D, Matthews P, Matayeva E, Kaufman JL, Steinman RM, Dhodapkar KM, Journal of Immunotherapy 2008 31 113 120 110.1097/CJI.1090b1013e31815a35892 10.1097/CJI.0b013e31815a5892 18481381
40. Stimulation of Th1-polarizing cytokines, C-C chemokines, maturation of dendritic cells, and adjuvant function by the peptide binding fragment of heat shock protein 70. Wang Y, Kelly CG, Singh M, McGowan EG, Carrara AS, Bergmeier LA, Lehner T, J Immunol 2002 169 2422 2429 12193710
41. A mouse model for the molecular characterization of brca1-associated ovarian carcinoma. Xing D, Orsulic S, Cancer research 2006 66 8949 8953 10.1158/0008-5472.CAN-06-1495 16982732
42. Kinetics of host cell recruitment during dissemination of diffuse malignant peritoneal mesothelioma. Miselis NR, Lau BW, Wu Z, Kane AB, Cancer microenvironment: official journal of the International Cancer Microenvironment Society 2010 4 39 50 21505561
43. Vaccination strategy determines the emergence and dominance of CD8+ T-cell epitopes in a FVB/N rat HER-2/neu mouse model of breast cancer. Singh R, Paterson Y, Cancer research 2006 66 7748 7757 10.1158/0008-5472.CAN-05-4469 16885378
44. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, Santosuosso M, Martin JD, Martin MR, Vianello F, Leblanc P, Munn LL, Huang P, Duda DG, Fukumura D, Jain RK, Poznansky MC, Proc Natl Acad Sci USA 2012 109 17561 17566 10.1073/pnas.1215397109 23045683
45. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Fields RC, Shimizu K, Mule JJ, Proc Natl Acad Sci USA 1998 95 9482 9487 10.1073/pnas.95.16.9482 9689106
46. Hsp70 promotes antigen-presenting cell function and converts T-cell tolerance to autoimmunity in vivo. Millar DG, Garza KM, Odermatt B, Elford AR, Ono N, Li Z, Ohashi PS, Nature medicine 2003 9 1469 1476 10.1038/nm962 14625545
47. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Delamarre L, Pack M, Chang H, Mellman I, Trombetta ES, Science 2005 307 1630 1634 10.1126/science.1108003 15761154
48. Mature dendritic cells use endocytic receptors to capture and present antigens. Platt CD, Ma JK, Chalouni C, Ebersold M, Bou-Reslan H, Carano RA, Mellman I, Delamarre L, Proc Natl Acad Sci USA 2010 107 4287 4292 10.1073/pnas.0910609107 20142498